Get daily US stock updates, expert commentary, and data-driven strategies designed to support smarter investment decisions and long-term portfolio growth. Our team works around the clock to bring you the most relevant and actionable information for your investment needs. We provide technical analysis, earnings forecasts, and risk management tools to help you navigate market volatility. Achieve your financial goals with our comprehensive platform offering professional-grade research, education, and support for free.
On April 27, 2026, AbbVie filed a supplemental Biologics License Application (sBLA) with the U.S. FDA for a subcutaneous (SC) induction dosing regimen of its top-selling immunology asset SKYRIZI for adults with moderately to severely active Crohn’s disease (CD), supported by positive Phase 3 AFFIRM
AbbVie Inc. (ABBV) Submits SKYRIZI Subcutaneous Crohn’s Regimen to FDA, But Near-Term Upside Remains Capped By Competitive Risks - Profit Growth Rate
ABBV - Stock Analysis
3005 Comments
1658 Likes
1
Thali
Elite Member
2 hours ago
This made sense in a parallel universe.
👍 205
Reply
2
Linie
Consistent User
5 hours ago
Anyone else following this closely?
👍 155
Reply
3
Maripaz
Daily Reader
1 day ago
Free US stock growth rate analysis and revenue trajectory projections for identifying fast-growing companies. Our growth research helps you find companies with accelerating momentum that could deliver exceptional returns.
👍 230
Reply
4
Shameka
Active Contributor
1 day ago
Free US stock growth rate analysis and revenue trajectory projections for identifying fast-growing companies. Our growth research helps you find companies with accelerating momentum that could deliver exceptional returns.
👍 173
Reply
5
Kadraya
Consistent User
2 days ago
Helpful insights for anyone following market trends.
👍 176
Reply
© 2026 Market Analysis. All data is for informational purposes only.